Health TrialsbyHealthPanel

Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus

ConditionSystemic Lupus Erythematosus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux

About this trial

The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age ≥ 18 years;

diagnosis of systemic lupus erythematosus;

being affiliated to health insurance, willing to participate and to sign informed consent;

control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.

Disqualifiers

pregnant or breastfeeding women;

patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Trial design

Design model

Parallel

Treatments tested in this trial

  • blood sample

    Biological/Vaccine

    30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Systemic lupus erythematosus (SLE)Experimental treatment 1 intervention
Group B: Rheumatoid arthritis or an inflammatory bowelActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects.

Time frame
At baseline (Day 0)

Secondary outcomes

1

Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects and controls.

Time frame
At baseline (Day 0)
2

Measurement of lipid peroxidation in other immune cells (T and B lymphocyte populations) in lupus subjects and controls

Time frame
At baseline (Day 0)
3

GPX4 expression in lupus subjects and controls.

Time frame
At baseline (Day 0)
4

Correlation between ferroptosis markers and the level of activity in B lymphocyte populations

Time frame
At baseline (Day 0)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Bordeaux

Lead sponsor

Source ClinicalTrials.gov
Apply now